In Review: PCMA attended the Maine Office of Affordable Health Care’s public hearing and provided verbal testimony. Our testimony pointed at drug manufacturers setting high list prices and patent thickets as the reason for prescription drug affordability issues in Maine. PCMA also met with Representative John “Jack” Ducharme (R) to discuss the 340B bill he is considering introducing. Rep. Ducharme asked PCMA for feedback on West Virginia’s SB 325 (2023), and we plan to follow up. PCMA also met with Representative Mike Soboleski (R) to provide him with a PBM 101. Rep. Soboleski is considering introducing a PBM bill similar to Alaska’s HB 226 (2023) but does not know much about the bill or the industry. PCMA will continue to contact Rep. Soboleski regarding our concerns about these anti-PBM policies in the Alaska bill.

If you have any questions, please contact Sam Hallemeier at shallemeier@pcmanet.org.